Phospho-JAK2 (Tyr931) Antibody

What is Phospho-JAK2 (Tyr931) Antibody and its research significance?

Phospho-JAK2 (Tyr931) antibody is a specialized immunological reagent that specifically recognizes JAK2 protein only when phosphorylated at tyrosine residue 931. This antibody is crucial for studying JAK2 signaling and activation states in various cellular processes. JAK2 (Janus Kinase 2) is a non-receptor tyrosine kinase involved in multiple signaling pathways, including cytokine receptor signaling, hematopoiesis, and immune regulation . Tyrosine 931 phosphorylation represents one of several post-translational modifications that regulate JAK2 activity. Detection of this specific phosphorylation site allows researchers to analyze the activation state of JAK2 in different experimental conditions and disease models .

What applications is Phospho-JAK2 (Tyr931) Antibody suitable for?

Phospho-JAK2 (Tyr931) antibody is validated for multiple experimental applications:

These applications enable researchers to investigate JAK2 phosphorylation status across different experimental systems, from cell lysates to tissue samples . The antibody has been validated to detect the expected band at approximately 130 kDa in Western blot analyses .

What is the specificity profile of Phospho-JAK2 (Tyr931) Antibody?

The Phospho-JAK2 (Tyr931) antibody specifically detects endogenous levels of JAK2 protein only when phosphorylated at tyrosine 931 . This high specificity is achieved through careful immunogen design and purification processes. The antibodies are typically produced against synthesized peptides derived from human JAK2 around the phosphorylation site of Tyr931, covering amino acid residues 906-955 .

To ensure specificity, manufacturers employ affinity purification methods using epitope-specific phosphopeptides. Non-phospho-specific antibodies are removed through chromatography using non-phosphopeptides . This meticulous production process ensures that the antibody exclusively recognizes the phosphorylated form of JAK2 at Tyr931, minimizing cross-reactivity with non-phosphorylated JAK2 or other phosphorylated proteins.

How should researchers optimize Western blot protocols for Phospho-JAK2 (Tyr931) Antibody?

For optimal Western blot results with Phospho-JAK2 (Tyr931) antibody, researchers should implement the following methodological considerations:

• Sample preparation: Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status. Use fresh samples when possible, as freeze-thaw cycles can reduce phosphoprotein stability.

• Protein loading: Load 20-40 μg of total protein per lane for cell lysates. Higher amounts may be needed for tissue samples with lower JAK2 expression.

• Blocking: Use 5% BSA in TBST rather than milk, as milk contains phosphoproteins that can interfere with phospho-specific antibody binding.

• Antibody dilution: Start with a 1:1000 dilution for Western blot applications, adjusting based on signal strength .

• Incubation conditions: Incubate with primary antibody overnight at 4°C to maximize specific binding.

• Controls: Include both positive controls (cells/tissues known to express phosphorylated JAK2) and negative controls (samples treated with phosphatase or JAK2 inhibitors).

This optimization strategy should yield a clear band at approximately 130 kDa, representing phosphorylated JAK2 at Tyr931 .

What are the best practices for immunohistochemistry and immunofluorescence using this antibody?

For successful immunohistochemistry (IHC) and immunofluorescence (IF) applications:

• Tissue fixation: Use 4% paraformaldehyde for optimal epitope preservation. Overfixation can mask phosphoepitopes.

• Antigen retrieval: Citrate buffer (pH 6.0) heat-mediated antigen retrieval is generally effective for phospho-epitopes.

• Dilution optimization: Start with 1:100 for IHC and 1:50 for IF, then optimize based on signal-to-noise ratio .

• Signal amplification: Consider tyramide signal amplification for low abundance phospho-proteins.

• Counterstaining: Use DAPI for nuclear visualization in IF applications.

• Controls: Adjacent serial sections should be processed without primary antibody. Additionally, include tissues with known JAK2 activation status.

• Documentation: Capture images at multiple magnifications, ensuring inclusion of regions with varying expression levels.

These methodological considerations help ensure specific detection of phosphorylated JAK2 (Tyr931) while minimizing background and non-specific staining.

How can Phospho-JAK2 (Tyr931) Antibody be integrated into JAK-STAT signaling pathway research?

Phospho-JAK2 (Tyr931) antibody serves as a valuable tool for dissecting JAK-STAT signaling dynamics through several advanced approaches:

• Temporal analysis: By combining this antibody with time-course experiments, researchers can track JAK2 phosphorylation kinetics following cytokine stimulation, revealing the sequence of activation events in the signaling cascade.

• Comparative phosphorylation analysis: Researchers can simultaneously analyze multiple JAK2 phosphorylation sites (Tyr931, Tyr1007/1008, Tyr868, Tyr966, and Tyr972) to understand their interdependencies and hierarchical relationships .

• Inhibitor studies: When used in conjunction with specific JAK inhibitors, this antibody helps elucidate the differential regulation of various phosphorylation sites and their biological significance.

• Crosstalk evaluation: By examining Tyr931 phosphorylation in response to stimuli that activate non-JAK-STAT pathways, researchers can identify signaling crosstalk mechanisms.

• Mutational analysis: Studies incorporating JAK2 mutants with substitutions at various tyrosine residues can reveal how Tyr931 phosphorylation influences or is influenced by other phosphorylation events .

This integrated approach enables comprehensive mapping of JAK2 activation mechanisms and their roles in downstream signaling events.

What is the relationship between JAK2 Tyr931 phosphorylation and other regulatory phosphorylation sites?

JAK2 functionality is regulated through a complex network of phosphorylation events that operate in concert:

• Activation loop phosphorylation: While Tyr1007/1008 phosphorylation in the activation loop is well-established as critical for JAK2 catalytic activity, Tyr931 phosphorylation appears to play a complementary regulatory role that modulates rather than initiates kinase activity .

• Hierarchical phosphorylation: Research suggests a sequential phosphorylation pattern where activation loop phosphorylation (Tyr1007/1008) precedes phosphorylation at sites like Tyr931, indicating a potential regulatory mechanism for fine-tuning JAK2 activity .

• Functional correlation: Phosphorylation of tyrosines 868, 966, and 972 has been shown to be required for maximal JAK2 kinase activity , suggesting potential cooperative interactions with Tyr931 phosphorylation.

• Pathway specificity: Different cytokines and growth factors may preferentially induce phosphorylation at specific sites. For instance, growth hormone stimulation has been associated with phosphorylation at Tyr868, Tyr966, and Tyr972 , while the specific stimuli predominantly responsible for Tyr931 phosphorylation warrant further investigation.

Understanding these interrelationships is crucial for mapping the complete regulatory network governing JAK2 function in health and disease.

How can researchers troubleshoot antibody specificity issues in complex experimental systems?

When facing specificity challenges with Phospho-JAK2 (Tyr931) antibody in complex systems:

• Peptide competition assay: Pre-incubate the antibody with excess phosphorylated peptide containing the Tyr931 epitope. Disappearance of the signal confirms specificity.

• Genetic validation: Utilize JAK2 knockout cells/tissues or JAK2 Y931F mutant expression systems as definitive negative controls to verify antibody specificity.

• Phosphatase treatment: Treat duplicate samples with lambda phosphatase to remove phosphorylation. Loss of signal confirms phospho-specificity.

• Multi-antibody validation: Compare results using antibodies from different vendors or clones that recognize the same phospho-epitope .

• Mass spectrometry correlation: For definitive validation, confirm antibody-based phosphorylation detection with mass spectrometry analysis of immunoprecipitated JAK2.

• Stimulus-response testing: Verify that signals increase following treatments known to activate JAK2 (e.g., cytokines, growth factors) and decrease with JAK inhibitors.

These validation strategies ensure that experimental observations truly reflect biologically relevant JAK2 Tyr931 phosphorylation events rather than technical artifacts.

What is the significance of JAK2 Tyr931 phosphorylation in hematological malignancies?

JAK2 signaling plays a central role in hematological malignancies, with phosphorylation at various sites serving as potential biomarkers and therapeutic targets:

• Myeloproliferative neoplasms: JAK2 mutations, particularly V617F, are commonly found in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. While most research focuses on activation loop phosphorylation, Tyr931 phosphorylation may serve as an additional biomarker for aberrant JAK2 activity .

• Leukemias: JAK2 is implicated in acute myelogenous leukemia (AML) and other leukemias through various mechanisms, including chromosomal translocations with PCM1 and ETV6 . Monitoring Tyr931 phosphorylation might provide insights into disease progression and treatment response.

• Budd-Chiari syndrome: JAK2 defects have been linked to this rare vascular disorder characterized by hepatic venous outflow obstruction . Understanding the phosphorylation profile, including at Tyr931, may contribute to improved diagnostic approaches.

• Therapeutic monitoring: As JAK inhibitors become increasingly important in treating myeloproliferative disorders, measuring specific phosphorylation sites like Tyr931 could help assess treatment efficacy and predict resistance mechanisms.

Research in this area continues to evolve, with phospho-specific antibodies becoming valuable tools for both basic research and potential clinical applications.

How does JAK2 Tyr931 phosphorylation integrate with broader cellular signaling networks?

JAK2 Tyr931 phosphorylation exists within a complex signaling ecosystem that integrates multiple pathways:

• Subcellular localization: JAK2 can be found in multiple cellular compartments, including the endomembrane system, cytoplasm, and nucleus , with phosphorylation potentially influencing its distribution and function in each location.

• Post-translational modification interplay: Beyond phosphorylation, JAK2 undergoes other modifications, including Notch-induced ubiquitination and subsequent proteasomal degradation . Tyr931 phosphorylation may influence or be influenced by these processes.

• Cytokine and growth factor crosstalk: JAK2 phosphorylation can be triggered by various stimuli, including erythropoietin, leptin, interferon gamma, and increased cellular retinol . The specific role of Tyr931 phosphorylation in these different contexts requires further investigation.

• Tissue-specific signaling: While JAK2 is ubiquitously expressed throughout most tissues , its phosphorylation patterns and functional consequences may vary in a tissue-specific manner, potentially explaining differential responses to JAK2-targeting therapeutics.

Understanding these complex interrelationships will contribute to more precise targeting of JAK2-dependent signaling in various pathological conditions.

What are the optimal storage and handling conditions for Phospho-JAK2 (Tyr931) Antibody?

To maintain antibody performance and extend shelf life:

• Storage temperature: Store at -20°C for up to one year from the date of receipt . Avoid repeated freeze-thaw cycles.

• Working aliquots: Upon receipt, prepare smaller working aliquots to minimize freeze-thaw cycles.

• Formulation: Most commercial Phospho-JAK2 (Tyr931) antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide , which helps maintain stability during storage.

• Shipping conditions: Antibodies are typically shipped with ice packs or dry ice. Upon arrival, immediately transfer to -20°C storage.

• Expiration tracking: Document receipt date and calculate expiration (typically one year when stored properly) .

• Concentration: Commercial preparations are typically supplied at 1 mg/ml concentration .

• Post-thaw handling: After thawing, briefly centrifuge vials before opening to collect all material at the bottom of the tube.

Proper storage and handling significantly impact experimental reproducibility and reliability when working with phospho-specific antibodies.

How can researchers validate Phospho-JAK2 (Tyr931) Antibody performance in their specific experimental system?

To ensure optimal antibody performance in your specific experimental system:

• Positive control selection: Choose cells/tissues with known JAK2 activation status. For Tyr931 phosphorylation, consider:

  • Cytokine-stimulated cell lines (e.g., HEL, K562 for hematopoietic studies)

  • Growth factor-treated epithelial cells

  • Tissues with high JAK2 activity (spleen, bone marrow)

• Dilution optimization: Perform a dilution series (e.g., 1:250, 1:500, 1:1000, 1:2000) to determine optimal concentration for your specific application .

• Signal verification methods:

  • JAK inhibitor treatment should reduce signal

  • Phosphatase treatment of samples should eliminate signal

  • JAK2 siRNA/shRNA knockdown should reduce signal

  • JAK2 activation (via cytokine stimulation) should increase signal

• Cross-reactivity assessment: Test the antibody against related JAK family members (JAK1, JAK3, TYK2) to confirm specificity for JAK2.

• Lot-to-lot consistency: When receiving a new lot, perform side-by-side comparison with previous lot using standardized samples.

This comprehensive validation approach ensures reliable and reproducible results across different experimental conditions and systems.